While patients with double-hit lymphoma (DHL) are now frequently treated with intensive front-line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative-intent second-line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression-free/overall survival (PFS/OS) of 2/5·1 months and one-year PFS/OS of 10/19% following the start of second-line therapy. These outcomes may serve as a standard against which future second-line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non-cytotoxic therapies in the second-line setting for these patients.

中文翻译：

---

强化前线免疫化学疗法失败后，采用根治性二线免疫化学疗法治疗的重击淋巴瘤患者的预后较差。

虽然现在经常使用强化的一线免疫化学疗法治疗双发性淋巴瘤（DHL）患者，但这些方法失败并随后接受治愈性二线免疫化学疗法的患者的预后尚不清楚。我们确定了55名这样的患者，他们的总体/完全缓解率达到29％/ 11％，中位无进展/总生存期（PFS / OS）为2/5·1个月，一年期PFS / OS为10/19开始二线治疗后的百分比。这些结果可作为衡量未来复发/难治性DHL二线治疗策略的标准，并证明对这些患者在二线治疗中对非细胞毒性疗法进行研究的合理性。